Skip to main content
DTIL
NASDAQ Life Sciences

Precision BioSciences' PBGENE-HBV Hits 100% pgRNA Clearance at 0.4 mg/kg, Moves to Phase 2

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$8.39
Mkt Cap
$226.838M
52W Low
$3.53
52W High
$9.62
52W Position info
138% above low
Off High info
13% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

DTIL has more than doubled off its 52-week low of $3.53.

Summary

Precision BioSciences reported Phase 1 hepatitis B data showing undetectable pgRNA in 100% of evaluable patients at the 0.4 mg/kg go-forward dose, plus biopsy evidence of cccDNA reduction, and said it is advancing to a global Phase 2. Its DMD program also cleared a DSMB safety review.


Key Events · Product Development and Regulatory · DTIL

  • PBGENE-HBV Clears pgRNA at Go-Forward Dose

    11 of 12 evaluable patients (92%) reached undetectable pgRNA, including all six evaluable at 0.4 mg/kg; the lone holdout had a 95% reduction after only two 0.65 mg/kg doses.

  • Biopsies Show cccDNA Reduction

    Paired liver biopsies at 0.4 mg/kg showed roughly 1-log (10-fold) and 1.5-log (35-fold) reductions in cccDNA, reproducing earlier EASL 2026 findings.

  • Phase 2 Dose Selected, Dosing Q1 2027

    0.4 mg/kg chosen for the global ELIMINATE-B2 Phase 2 study, testing monotherapy and combination with an ASO; dosing expected to begin Q1 2027 with initial open-label data in H2 2027.

  • DMD Program Clears DSMB Review

    First PBGENE-DMD patient completed eight weeks with no serious adverse events or adverse events of special interest; the DSMB endorsed dosing additional patients in Part 1.


Analysis · DTIL · Life Sciences

This is the first hard efficacy readout on PBGENE-HBV, the company's wholly owned hepatitis B program and the main driver of its valuation. At the 0.4 mg/kg go-forward dose, all six evaluable patients cleared pgRNA to undetectable, and paired liver biopsies showed 1-log to 1.5-log cccDNA reductions — direct evidence the drug does what it was designed to do. The first HBeAg-positive patient, a population with 2-3 log higher cccDNA burden, also cleared pgRNA from a 3.7-log baseline. With no dose-limiting toxicities across 59 administrations, the company has picked 0.4 mg/kg for a global Phase 2 (ELIMINATE-B2) with dosing expected in Q1 2027. Separately, the DMD program cleared its first safety hurdle: the DSMB endorsed dosing more patients after the first patient finished eight weeks with no serious adverse events. Both programs now have a funded path (cash runway guided through 2028), so the next real test is whether Phase 2 cure rates hold up in H2 2027.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DTIL was trading at $8.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $226.8M. The 52-week trading range was $3.53 to $9.62. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DTIL - Latest Insights

DTIL
Nov 05, 2026, 7:10 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $7.73
Real-time Price: $6.87 info
Change: -$0.860 (-11%) info
Market Cap: $190.522M info
DTIL
Nov 05, 2026, 7:07 AM EST
Filing Type: FWP
Importance Score:
7
Price at Filing: $8.50
Real-time Price: $6.87 info
Change: -$1.63 (-19%) info
Market Cap: $190.522M info
DTIL
Nov 05, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $8.57
Real-time Price: $6.87 info
Change: -$1.70 (-20%) info
Market Cap: $190.522M info
DTIL
Nov 05, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $8.39
Real-time Price: $6.87 info
Change: -$1.52 (-18%) info
Market Cap: $190.522M info
DTIL
Nov 03, 2026, 8:58 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $7.33
Real-time Price: $6.87 info
Change: -$0.460 (-6%) info
Market Cap: $190.522M info